One bright spot for ITMN that hasn’t received any attention is that Roche recently licensed ITMN’s second-generation HCV protease inhibitor, which is in preclinical development and is as yet unnamed. A cynic might say that even this development is a negative, however. If Roche were happy with ITMN-191, why would they need another PI?
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”